{"filings":[{"id":94304,"accession_number":"0001638833-26-000044","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue $810.9M (+4.5%), net loss $35.9M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $810.9M (+4.5% YoY); same-facility revenue +4.4% on 0.6% case growth and 3.8% revenue per case.","Net loss attributable to Surgery Partners $35.9M; Adjusted EBITDA $102.3M vs $103.9M YoY.","Full-year 2026 guidance reaffirmed: revenue $3.35-3.45B, Adj. EBITDA at least $530M.","Cash and equivalents $182.3M; revolver capacity $666.1M; net debt/EBITDA ratio 4.3x.","Operating cash flow $11.7M in Q1 vs $6.0M YoY on working capital timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":810900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106554,"accession_number":"0001638833-26-000006","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Surgery Partners Q4 rev $885M (+2.4%), Adj. EBITDA $156.9M (-4.2%), net loss $15M, 2026 guidance, $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $885.0M (+2.4% YoY); full-year $3.3B (+6.2%). Same-facility revenue +3.5% Q4.","Adj. EBITDA $156.9M (-4.2% YoY); full-year $526.2M (+3.5%). Net loss $15.0M Q4, $77.9M FY.","2026 guidance: Adj. EBITDA at least $530M; revenue range $3.35B-$3.45B.","Board authorized $200M share repurchase program on February 26, 2026.","Operating cash flow $103.4M Q4 (down from $111.4M); net debt/EBITDA ~4.3x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122894,"accession_number":"0001104659-25-121563","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners subsidiary issues additional $425M of 7.25% Senior Notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Surgery Center Holdings issued $425M add-on to existing 7.250% Senior Notes due 2032; total now $1.225B.","Notes are fungible with $800M series issued April 2024 under same CUSIP (Reg S separate for 40 days).","Issued under Third Supplemental Indenture with Wilmington Trust, National Association as trustee.","Use of proceeds not disclosed in the filing.","Notes rank equally with existing unsecured obligations of the issuer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122893,"accession_number":"0001104659-25-120386","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary prices $425M add-on of 7.250% senior notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuer Surgery Center Holdings priced $425M aggregate principal of 7.250% senior unsecured notes due 2032.","Notes are part of same series as $800M notes originally issued in April 2024.","Net proceeds to be used for general corporate purposes, including repaying revolving credit facility.","Offering expected to close on December 16, 2025, subject to customary conditions.","Notes guaranteed on senior unsecured basis by domestic wholly-owned subsidiaries that guarantee senior secured credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122892,"accession_number":"0001104659-25-120159","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary to offer $425M add-on 7.250% senior notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Intent to offer $425M additional 7.250% Senior Notes due 2032, same series as April 2024 issuance.","Net proceeds used for general corporate purposes, including repaying revolver borrowings.","Notes guaranteed on senior unsecured basis by domestic subsidiaries that guarantee credit facilities.","Offering conducted under Rule 144A and Regulation S; notes not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122891,"accession_number":"0001638833-25-000166","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Surgery Partners appoints Justin Oppenheimer as COO and National Group President effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Oppenheimer joins from Hospital for Special Surgery, where he was Chief Strategy Officer and COO.","Base salary of $660,000, signing bonus of $500,000 (subject to repayment if resigns within 1 year).","Eligible for annual bonus target of 100% of base salary; annual equity target of $1.5M.","Initial equity grant of $1.25M in restricted stock vesting on first anniversary.","Reports to CEO; severance includes 12 months base salary plus benefits for without-cause termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122890,"accession_number":"0001638833-25-000159","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue up 6.6% to $821.5M, net loss $22.7M; FY guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $821.5M (+6.6% YoY); same-facility revenue +6.3%, cases +3.4%.","Net loss attributable to SGRY of $22.7M; Adjusted EBITDA $136.4M (+6.1% YoY).","Full-year 2025 guidance: revenue $3.275-3.30B, Adjusted EBITDA $535-540M (revised down).","Leverage ratio 4.2x net debt/EBITDA; Q3 operating cash flow $83.6M vs $65.2M YoY.","Management cites softer volume, payor mix, and delayed capital deployment for guidance revision."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2423700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139591,"accession_number":"0001638833-25-000153","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surgery Partners' National Group President Harrison R. Bane resigns effective Oct 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harrison R. Bane, National Group President, resigns effective October 3, 2025.","Resignation is not due to any disagreement with the company on operations, policies, or practices.","No successor has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139590,"accession_number":"0001104659-25-077656","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners closes $1.383B term loan refinancing; extends maturities to 2030/2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.383B 2025 Refinancing Term Loans replace existing term loans; maturity extended to Dec 19, 2030.","Revolving credit commitments refinanced; new 2025 Refinancing Revolving Loans mature Dec 19, 2028.","Interest rate: Term SOFR + 2.50% or alternate base rate + 1.50%.","Term loans amortize in equal quarterly installments of 0.25% of original principal starting Q3 2025.","Voluntary prepayment permitted with 1% call premium for repricing events within first 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139589,"accession_number":"0001638833-25-000138","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surgery Partners Chairman Wayne DeVeydt resigns; Blair Hendrix named new Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wayne S. DeVeydt resigned as director and Executive Chairman effective August 4, 2025.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Board appointed Blair E. Hendrix as Chairman of the Board effective immediately.","Board reduced size from 11 to 10 directors concurrent with resignation.","No replacement for the vacant board seat announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139588,"accession_number":"0001638833-25-000132","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue up 8.4% to $826.2M; Adj EBITDA $129M, up 9%; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $826.2M (+8.4% YoY); same-facility revenue +5.1%, same-facility cases +3.4%.","Adjusted EBITDA $129.0M (+9.0% YoY); net loss attributable to Surgery Partners $2.5M.","Full-year 2025 guidance reaffirmed: revenue $3.30-3.45B, Adjusted EBITDA $555-565M.","Cash $250.1M and $394.9M revolver capacity at June 30, 2025; net debt/EBITDA 4.1x.","CEO cites active evaluation of portfolio optimization to reduce leverage and accelerate cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1602200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157170,"accession_number":"0001638833-25-000117","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners ends Bain Capital buyout talks; reaffirms 2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Committee determined that remaining independent provides greater long-term value than Bain Capital's acquisition proposal.","Company reaffirms 2025 revenue guidance of $3.30B-$3.45B and Adjusted EBITDA of $555M-$565M.","Surgery Partners plans to host an Investor Day in H2 2025 to detail growth strategy.","Bain Capital remains a long-term investor and collaborator despite no deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157169,"accession_number":"0001638833-25-000096","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Surgery Partners shareholders re-elect three directors and approve 2025 incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt as Class I directors for three-year terms.","Advisory vote on executive compensation approved with ~96.6M votes for and ~19.2M against.","2025 Omnibus Incentive Plan approved with ~101.7M votes for, ~14.0M against.","Ratification of Ernst & Young as independent auditor for FY2025 passed with ~122.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157168,"accession_number":"0001638833-25-000089","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue up 8.2% to $776M; Adj EBITDA $103.9M (+6.6%); net loss $37.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Same-facility revenue +5.2%, same-facility cases +6.5% YoY; revenue per case -1.2%.","Net loss attributable to Surgery Partners $37.7M; no GAAP EPS provided.","Adjusted EBITDA $103.9M vs. $97.5M in prior-year quarter (+6.6%).","Full-year 2025 guidance reaffirmed: revenue $3.30-$3.45B, Adj EBITDA $555-$565M.","Cash $229.3M + $388.9M revolver capacity; net debt/EBITDA ~4.1x; operating cash flow $6.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":776000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175519,"accession_number":"0001638833-25-000031","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q4 revenue up 17.5% to $864.4M; Adj EBITDA +15.1%; sets 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $864.4M (+17.5% YoY); full-year revenue $3.1B (+13.5% YoY).","Q4 adjusted EBITDA $163.8M (+15.1%); full-year $508.2M (+16.0%).","Same-facility revenue growth 5.6% in Q4, 8.0% full year; cases +5.1% and +3.9% respectively.","Net loss attributable $108.5M Q4, $168.1M full year; includes non-cash tax valuation allowance. No federal income taxes expected until 2029.","2025 guidance: revenue $3.30-$3.45B; Adj EBITDA $555-$565M. Liquidity >$770M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175518,"accession_number":"0001104659-25-006658","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Surgery Partners receives $25.75/share buyout proposal from Bain Capital; Bain owns ~39%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bain Capital proposes to acquire all outstanding shares not already owned for $25.75 per share in cash.","Bain Capital and affiliates own approximately 39% of Surgery Partners' outstanding common stock.","A Special Committee of independent directors will evaluate the proposal with advisors.","Any transaction subject to non-waivable condition requiring majority approval of shares not owned by Bain.","Proposal is non-binding; no assurance that a definitive agreement will be reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175517,"accession_number":"0001638833-25-000002","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Surgery Partners appoints Dr. Laura L. Forese to Board of Directors, effective Jan 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Forese, former EVP and COO of New York-Presbyterian, appointed as independent director.","Board size increases to 11 members; she fills a Class II vacancy, term expires at 2026 annual meeting.","She will serve on the Compliance and Ethics Committee; compensation consistent with other non-employee directors.","Dr. Forese is an orthopedic surgeon with over 40 years of healthcare administration experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192473,"accession_number":"0001638833-24-000143","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue $770.4M (+14.3% YoY); adjusted EBITDA $128.6M (+21.9%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $770.4M, +14.3% YoY; same-facility revenue +4.2% on 3.7% case growth.","Adjusted EBITDA $128.6M, +21.9% YoY; margin 16.7%, expanding 100 bps.","Net loss attributable to Surgery Partners was $31.7M.","FY 2024 outlook reaffirmed: revenue >$3.075B, adjusted EBITDA >$508M.","Cash $221.8M, revolver capacity $595.8M; total net debt/EBITDA 3.8x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":2249900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208941,"accession_number":"0001638833-24-000137","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Surgery Partners dismisses Deloitte, engages EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor effective Aug 21, 2024; no adverse opinions or disagreements.","Ernst & Young appointed as new independent registered public accounting firm for fiscal year ending Dec 31, 2024.","No reportable events or disagreements with Deloitte during fiscal 2022-2023 and subsequent interim period.","Deloitte provided letter agreeing with company's statements, filed as Exhibit 16."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208940,"accession_number":"0001638833-24-000132","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue +14.2% to $762.1M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $762.1M (+14.2% YoY); same-facility revenue up 9.9%, cases up 3.9%.","Adjusted EBITDA $118.3M (+18.1%); margin 15.5% (+50 bps).","Net loss attributable to company $15.5M.","FY2024 guidance raised: revenue >$3.075B, Adjusted EBITDA >$508M.","Deployed ~$220M on acquisitions YTD; balance sheet refinanced and hedged."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1479500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226763,"accession_number":"0001104659-24-073419","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners closes $1.4B term loan refinancing, extending maturity to 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.4B aggregate principal of 2024 Refinancing Term Loans priced at Term SOFR + 2.75% or base rate + 1.75%.","New loans mature December 19, 2030 and replace all existing term loans under the credit agreement.","Amortization: equal quarterly installments of 0.25% of original principal, starting Q3 2024.","Voluntary prepayments subject to 1% call premium if made within 6 months due to a repricing event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226762,"accession_number":"0001638833-24-000127","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surgery Partners shareholders approve all four proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Class III directors Clifford Adlerz, J. Eric Evans, Blair Hendrix, and Andrew Kaplan.","Advisory vote on executive compensation passed with ~121.2M for, ~1.1M against.","Employee stock purchase plan approved (~122.2M for); plan qualified under Section 423.","Appointment of Deloitte & Touche as 2024 auditor ratified (~124.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226761,"accession_number":"0001638833-24-000110","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue up 7.7% to $717.4M, Adjusted EBITDA $97.5M; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.4M; Adjusted EBITDA $97.5M (+8.2% YoY); margin 13.6%.","Same-facility revenue +10.2% YoY with 8.8% revenue per case increase and 1.3% case growth.","FY 2024 guidance raised: revenue at least $3.05B, Adjusted EBITDA at least $505M.","Completed refinancing of term loan and unsecured notes; no material debt maturities until 2030.","Cash $185.2M; revolver capacity $607.3M; net debt/EBITDA ratio ~3.5x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":717400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}